Android
Zerodha Broker (Free Delivery)

India's No. 1 Broker with Best Software Trade @ Flat Rs 20

Open Instant Account
market update arrow Rajasthan political crisis LIVE: Sachin Pilot is now in BJP, says PL Punia arrow RIL hits new high on closing deals with 4 investors; m-cap above Rs 12 trn arrow MARKET LIVE: Sensex rises 350 points; Tech Mahindra, RIL top gainers arrow MARKET LIVE: Sensex rises 350 points; Tech Mahindra, RIL top gainers arrow Coronavirus vaccine update: Russia completes world's first human trial arrow Google for India 2020 event to kickstart at 2 pm: Watch livestream and more arrow YES Bank declines for second straight day, slips 17% on heavy volumes arrow Clariant Chemicals up 18%, hits 52-wk high on special dividend of Rs 140/sh arrow Economic recovery to gather pace in H2-2020; stay negative on India: Nomura arrow Economic recovery to gather pace in H2-2020; stay negative on India: Nomura arrow Nifty topline may dip up to 25% YoY; banks, telecom, agrochem silver lining arrow Nifty topline may dip up to 25% YoY; banks, telecom, agrochem silver lining arrow Biocon hits new high on DGCI nod to market Itolizumab for Covid treatment arrow Trai blocks Airtel, Vodafone Idea plans promising faster data speeds arrow Trai blocks Airtel, Vodafone Idea plans promising faster data speeds arrow Samsung Galaxy Tab S6 Lite review: Big screen slate for work, play and more arrow Coronavirus LIVE: India logs biggest single-day spike with 28701 news cases arrow Rossari Biotech IPO: Why Covid-19 outbreak may be positive for the company arrow Rossari Biotech IPO: Why Covid-19 outbreak may be positive for the company arrow Comet Neowise to be visible in Indian skies for 20 days starting July 14 arrow Best of BS Opinion: Minerals in our solar future, climate change, and more arrow ReNew Power gives salary hikes of up to 12% to staff amid Covid-19 crisis

DIVI'S LABORATORIES LTD. 2211.10 8.00 (0.36%)

  • BSE: 532488
  • |
  • NSE: DIVISLAB
  • |
  • ISIN NO: INE361B01024
  • |
  • INDUSTRY: Pharmaceuticals
Profile

DIVISLAB

Divis Laboratories Limited or DIVISLAB

Divis Laboratories was established in 1990; it manufactures the Active Pharma Ingredients (APIs) and intermediates. It focuses on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. The company has expanded its breadth of working operations in a short period with the purpose to provide complete turnkey solutions to the Indian Pharmaceutical Industry. And with the five years of ... experience, and expertise, and a proven track–a record of helping many companies with its turnkey and consulting strengths, it had also established its first manufacturing facility in 1995. Its manufacturing plant is built on a 300-acre site at Hyderabad and its second manufacturing plant is located in Vishakhapatnam on a 314-acre site. It also has a presence in both New Jersey as well as Switzerland.

Currently, both the facilities are engaged in the manufacture of given components:

  1. Active Pharmaceutical Ingredients (APIs) & Intermediates for Generics
  2. The Custom Synthesis of API's and Advanced intermediates for discovery compounds for pharma giants
  3. Building blocks for Peptides
  4. Building blocks for Nucleotides
  5. Carotenoids
  6. Chiral ligands
The Company in Hyderabad has also been successfully inspected by the US FDA during September 2000, in April 2004 and even in February 2008. Whereas it's Unit–2 is situated at Visakhapatnam and was also successfully inspected by the US FDA during November 2006 and in April 2009. It also undertakes various FTE/Contract Research on process development for the discovery of new compounds for the leading M.N.C.s across the globe and their consecutive partners for the supply of APIs. The company is global in its outlook & it benchmarks the quality standards, which are the best in the world. In April 2010, it also received the letter of approval from the Development Commissioner, Visakhapatnam Special Economic Zone, regarding setting up and development of a new manufacturing Unit for pharma ingredients with an estimated investment of INR 200 crore.

Various Businesses of the company:

  1. Generics – It manufactures the API's for the Generics, and as a company, it understands that continued development is not possible without respecting I.P.R. So, the Divis takes excellent care to ensure that its products or various processes do not infringe the valid patents.
  2. Intermediates – It supplies advanced intermediates for most of the generic APIs that are already out of patent, as also for those APIs that are about to enter generic status shortly. So, it has tie-ups with both original inventors as well as with the generic API manufacturers too.
  3. Protected Amino Acids – It has built up a strong base in the manufacture of B.O.C., FMOC, and C.B.Z. Protected amino acids, and the protecting reagents themselves, and the peptide condensing agents who are synthetic, and is natural and novel unnatural amino–acids & oligopeptides.
It has invested heavily in knowledge, equipment, and workforce to expand in this particular technology area, which is both sophisticated and challenging, but of course, rewarding. Currently, Divis is also a significant manufacturer of the protected amino–acids.
  1. Chiral Synthesis – It is an established & proven expertise in the stereoselective synthesis using chiral ligands, and high yield resolutions using chirally active resolving agents, recovery of determining agents and ligands, recycling of undesirable isomers, recommendations which involve the enzymes and also do the manufacture of novel ligands such as binol, and binap and so much more.
  2. Carotenoids (Synthetic) and Nutraceuticals – It has succeeded in developing a multistep total synthesis of essential carotenoids such as Apocarotenal, Betacarotene, Lycopene, Astaxanthin, Canthaxanthin, and more.

Products:

Divis manufacture API's for the Generics. As a company, Divis understand that continued development is not possible without respect to I.P.R. Divis takes excellent care to ensure that its product or the processes which do not infringe valid patents. Here are some of the products:
  1. Bupropion Hbr
  2. Bupropion H.C.L.
  3. Capecitabine
  4. Carbidopa
  5. Desloratadine
  6. Dexlansoprazole /(R)–Lansoprazole
  7. Dextromethorphan Base
  8. Dextromethorphan HBr
  9. Diltiazem H.C.L.
  10. Fexofenadine
  11. Fosphenytoin Sodium
  12. Gabapentin
  13. Iopamidol

The Milestones:

  1. 2008: The KFDA inspects the Visakhapatnam (Unit–2) for the first time.
  2. 2009: KFDA examines the Visakhapatnam (Unit–2) for the second time.
  3. 2009:S.–F.D.A. inspects the Visakhapatnam (Unit–2) for the second time.
  4. 2010: Divis Laboratories received a letter of approval for establishment and also the development of a new manufacturing Unit there for pharma ingredients

Awards:

  1. 2009: It was Certified and Awarded for the 'Best Green Belt Development' by the A.P.Pollution Control Board on behalf of the Government of Andhra Pradesh.
  2. 2009: The SURAKSHA PURASKAR for the year 2008 by NATIONAL SAFETY COUNCIL NSCI SAFETY AWARDS.
  3. 2008: The FINALIST CERTIFICATE by Golden Peacock Environment Management Award.
  4. 2007: The UNNER–UP Under Scheme No 1 of the National Safety Awards 2006 by the Government of India, Ministry of Labour & Employment National Safety Awards (N.S.A.).
  5. 2005: The National Award for Excellence Water Management 2005 by Confederation of Indian Industry (CII).

Read More
Key Data
  • Market cap 62405.00 CR.
  • Book value 275.61
  • Stock P/E 43
  • Dividend Yield 0.68%
  • ROCE 27.66%
  • ROE 20.32%
  • Sales Growth (3Y) 9.47%
  • Face Value (3Y) 2.00
Trend Analysis
  • Short Term Trend :
    Down
  • Medium Term Trend :
    Down
  • Long Term Trend :
    Not Clear

Are you friends with trend?

There is a saying in stock market, "Trend is your best friend"

It means, a good trader doesn't place his money against the trend. Many new traders lose money because they are trying to catch trend reversals but seasoned traders wait for a clear trend to emerge before taking the trade in the direction of trend.

Day Technicals

What is Opening Range Breakout?

An opening range breakout is breaking out of the day's range after a stock has moved for some time in a sideways trend. In technical terms, its a breakout from the support and resistance level in an upward or downward trend.

NR7

What is NR7 trading strategy?

Narrow Range trading strategy or NR7 Trading strategy is a breakout based method which assumes that the price of security trends up or down after a brief consolidation in a narrow range.

Opening Price clues

How to use Opening Price Clues in your trades?

If the stock has same open and high after it has traded for some time, it implies there was a consistent selling pressure that didn't allow the stock to move higher from the opening price. Similarly, if the stock has same open and low price, it implies there was a consistent buying intent that kept the stock price above the opening price.

Day High Low Range
TIME LOWEST HIGHEST
10 AM 2197.20 2225.00
11 AM 2197.20 2236.90
12 PM - -
1 PM - -
2 PM - -
3 PM - -
Japanese Candlestick Patterns
Candle Pattern 1 :None
Candle Pattern 2 : None
Candle Pattern 3 :None
Candlestick Price Action
Higher High Higher Low
Pivot Points
Name S4 S3 S2 S1 Pivot Points R1 R2 R3 R4
classic 1996.77 2063.37 2129.97 2166.53 2196.57 2233.13 2263.17 2329.77 2396.37
woodie's 2017.84 2084.44 2122.22 2151.05 2188.82 2217.65 2255.42 2284.25 2350.85
fibonacci - 2129.97 2155.39 2171.13 2196.57 2222.01 2237.74 2263.17 -
camarilla 2166.47 2184.78 2190.89 2197.00 -- 2209.20 2215.31 2221.42 2239.73
Past Performance & Moving Averages
Day’s LOW HIGH RANGE SMA PERFORMANCE Nifty
10 DAY 2090.05
2368.00
2211.24 1.01 % 1.94 %
20 DAY 2090.05
2449.60
2271.75 -5.12 % 4.53 %
50 DAY 2090.05
2537.95
2320.41 -3.69 % 19.69 %
100 DAY 1626.00
2537.95
2226.60 14.67 % 28.79 %
200 DAY 1575.10
2537.95
2012.93 21.80 % -11.15 %
YTD 1626.00
2537.95
2154.03 21.32 % -11.49 %
52 Week 1460.10
2537.95
1837.59 37.69 % -6.63 %

Why are moving Averages important in technical Analysis?

An opening range breakout is breaking out of the day's range after a stock has moved for some time in a sideways trend. In technical terms, its a breakout from the support and resistance level in an upward or downward trend.

Gaps On Day Chart
Unfilled Gap Up On 2018-10-29
1324.85 ~ 1278.40 SUPPORT
Unfilled Gap Up On 2017-11-02
1016.00 ~ 933.45 SUPPORT
Unfilled Gap Up On 2017-08-28
678.40 ~ 676.00 SUPPORT
Industry Growth Rate

In Last 1 Year the industry has grown by 11.39 %

In Last 5 Year the industry has grown by 12.47 %

Peer comparison

Sales

COMPANY NAME 2014 2015 2016 2017 2018 2019
DIVISLAB 2532.00 3115.00 3776.00 4064.00 3891.00 4946.00
SUNPHARMA 16080.00 27392.00 28487.00 31578.00 26489.00 29066.00
LUPIN 11286.00 12770.00 14256.00 17367.00 15797.00 16718.00
CIPLA 10173.00 11345.00 13790.00 14394.00 15156.00 16362.00
AUROPHARMA 8089.00 12103.00 13772.00 14910.00 16463.00 19564.00
Total 9632.00 13345.00 14816.20 16462.60 15559.20 17331.20

Financial

LAST FISCAL CURRENT GROWTH 10 YEAR CAGR
S.NO. COMPANY NAME MARKET CAP CMP BOOK VALUE EPS STOCK P/E ROE ICR REVENUE NET PROFIT NPM REVENUE NET PROFIT REVENUE NET PROFIT
1 SUN PHARMACEUTICAL INDUSTRIES LTD. 83278.97 347.05 98.33 11.11 38.37 11.10 11.45% 29066.00 2665.00 9.17% 9.73% 27.15% 21.39% 3.90%
2 MARKSANS PHARMA LTD. 92969.02 22.65 11.85 1.87 10.83 1.85 13.20% 1000.00 76.00 7.60% 9.53% 130.30% 10.88%
3 MOREPEN LABORATORIES LTD. 71575.87 15.90 6.43 0.64 23.05 0.32 34.00% 769.00 29.00 3.77% 26.69% 15.56%
4 NEULAND LABORATORIES LTD. 50071.35 390.75 542.16 12.74 36.68 1.23 3.63% 667.00 16.00 2.40% 26.57% 33.33% 8.07% 2.92%
5 GUFIC BIOSCIENCES LTD. 41419.69 53.30 10.85
6 DIVI'S LABORATORIES LTD. 58563.64 2207.00 266.77 50.96 38.52 25.53 374.60% 4946.00 1353.00 27.36% 27.11% 54.28% 15.41% 12.49%
7 DR.REDDY'S LABORATORIES LTD. 64828.66 3902.10 852.69 117.47 26.67 23.49 35.71% 15448.00 1950.00 12.62% 8.17% 105.91% 8.45%
8 RPG LIFE SCIENCES LTD. 41788.21 252.45 105.02
9 SMS PHARMACEUTICALS LTD. 34236.68 40.25 42.07 4.73 8.97 5.00 7.50% 465.00 40.00 8.60% 0.43% 25.00%
10 CIPLA LTD. 51473.01 638.65 209.71 18.96 23.60 9.49 18.43% 16362.00 1528.00 9.34% 7.96% 8.29% 12.67% 7.08%
11 TORRENT PHARMACEUTICALS LTD. 39832.14 2352.75 323.66 25.78 77.62 5.13 3.86% 7673.00 436.00 5.68% 28.96% 16.89% 9.01%
12 PIRAMAL ENTERPRISES LTD. 32592.23 1445.00 823.58 70.51 20.69 39.81 1.61% 13215.00 1473.00 11.15% 24.31% 15.08% 16.64%
13 LUPIN LTD. 39002.40 860.75 384.76 13.40 53.92 6.74 9.28% 16718.00 607.00 3.63% 5.83% 141.83% 16.04% 1.92%
14 NECTAR LIFESCIENCES LTD. 29495.44 13.16 49.89 2.12 6.56 2.18 1.78% 2779.00 48.00 1.73% 48.29% 14.38%
15 AUROBINDO PHARMA LTD. 48052.55 820.50 206.07 40.36 12.59 40.08 15.03% 19564.00 2365.00 12.09% 18.84% 20.53% 37.21%
16 Alkem Laboratories Ltd 29145.20 2427.75 501.34 63.61 37.53 31.71 20.36% 7357.00 761.00 10.34% 14.94% 20.60%
17 ABBOTT INDIA LTD. 33072.92 15511.05 1004.00
18 CADILA HEALTHCARE LTD. 36556.99 356.95 90.85 18.05 15.05 18.13 15.32% 13166.00 1849.00 14.04% 10.59% 4.11% 16.49% 19.83%
19 GLAXOSMITHKLINE PHARMACEUTICALS LTD. 25185.05 1487.00 138.61 26.29 52.38 2.63 581.00% 3128.00 445.00 14.23% 8.95% 26.78%
20 KILITCH DRUGS (INDIA) LTD. 13893.00 89.90 98.74 2.49 51.55 0.25 11.22% 82.40 3.83 4.65% 61.70%
Sales

What is Sales Trend ?

Sales trend is a methodology to understand sales results which helps in understanding the trends of the market over a specific period of time. Sales results are an indicative of the sales patterns followed by the customer over a time period.

Profitability

What is Profit & EPS Trend ?

EPS Trends was initially built in late 2015 when I was just getting into frontend development. Coming from a background in Rails, I was frustrated with how many decisions you had to make early on as a javascript developer.

Net Profit
EPS

What is EBITDA Margin & EBIT Margin ?

Corporate accounting is required to adhere to the standards and practices collectively referred to as the generally accepted accounting principles. EBITDA is an excellent way for corporate accountants to start compiling data, but it should not be considered an absolute result. This is due to the fact that many consider EBITDA more of a broad stroke than a definitive form of accounting practice.

EBITDA Margin
EBIT Margin
NPM
Cash Flow

Why is the Cash Flow Analysis important?

A business needs cash to pay its expenses, to pay bank loans, to pay taxes and to purchase new assets. A cash flow report determines whether a business has enough cash to do exactly this.

Operating Activities
Financing Activities
Investing Activities
Financial Health

What Is Financial Health?

Financial health is a term used to describe the state of one's personal monetary affairs. There are many dimensions to financial health, including the amount of savings you have, how much you’re putting away for retirement, and how much of your income you are spending on fixed or non-discretionary expenses.

Debt to Equity
Piotroski Score
  • 0
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9

What Is the Piotroski Score?

The Piotroski score is a discrete score between 0-9 that reflects nine criteria used to determine the strength of a firm's financial position.

Altman Z Score (Mfg Company)
  • Distress (< 1.81)
  • Caution (>1.81 < 2.99)
  • 7.45
    Safe (3 & above)
Altman Z Score (Non-Mfg Company)
  • Distress ( < 1.23)
  • Caution (>1.23 < 2.6)
  • 13.79
    Safe (2.6 & above)
Valuation

What Is Valuation?

Valuation is the analytical process of determining the current (or projected) worth of an asset or a company. There are many techniques used for doing a valuation. An analyst placing a value on a company looks at the business's management, the composition of its capital structure, the prospect of future earnings, and the market value of its assets, among other metrics.

DIVISLAB: Future
TRADING SYMBOL OI VOLUME LAST PRICE LOT SIZE EXPIRY DATE
DIVISLAB20JULFUT 4573600.00 638800.00 2210.55 400 2020-07-30
DIVISLAB20AUGFUT 45200.00 18400.00 2218.00 400 2020-08-27
DIVISLAB20SEPFUT 7600.00 1600.00 2230.60 400 2020-09-24
ROLLOVER COST: 0.34% (INR 7.45)
ROLLOVER%:1.14%
What is the significance of Rollover data?

Rollover in an important data point and should be analyzed in the expiry week. Rollover involves carry forwarding of ‘futures’ positions from one series (which is nearing expiry date) to the next one.

Rollover percentage actually indicates whether the traders are willing to carry forward their existing. positions (long or short) to the next series or not. Generally, the rollover figures alone will not indicate which direction traders are betting on. You should also check whether absolute open interest is increasing or decreasing over expiries

What is Options Max Pain Theory?

Options Max Pain Theory suggests,

“On option expiration day, the underlying stock price often moves toward a point that brings maximum loss to option buyers.”

Ratio Analysis

The Bank was incorporated in the year 2004 by Rana Kapoor and Late Ashok Kapur, which is a new age private sector bank. And since the inception of the bank has fructified into a “Full-Service Commercial Bank,” it has steadily built Corporate and Institutional Banking, Financial Markets, Investment Banking, Corporate Finance, Branch Banking, Business and Transaction Banking, and Wealth Management business lines across the whole country.

It is well-equipped to offer a spectrum of products and services to all the corporate and retail customers.

Read More
Bulk Deals
Symbol Name Deal Date Client Name Transcation Type Quantity Price
DIVISLAB 2007-05-22 MERRILL LYNCH CAPITAL MARKETS ESPANA S.A. S.V. P 67649.00 3939.93
DIVISLAB 2006-07-18 GOLDMAN SACHS AND CO SUB S 75000.00 1260.04
DIVISLAB 2006-06-28 GOLDMAN SACHS INVESTMENT P 218950.00 1250.00
DIVISLAB 2006-06-28 LLYOD GEORGE INVESTMENT M S 218950.00 1250.00
DIVISLAB 2005-04-18 MERRILL LYNCH CAPITAL MAR P 90000.00 978.50
DIVISLAB 2005-04-18 FIDELITY MANAGEMENT AND R S 90922.00 978.49
DIVISLAB 2004-12-08 OPPENHEIMER FUNDS P 123216.00 1139.00
DIVISLAB 2004-12-08 THE EMERGING MARKET MANAG S 123216.00 1139.00
Block Deals
Symbol Name Deal Date Client Name Transcation Type Quantity Price
DIVISLAB 2009-03-26 SLOANE ROBINSON INVESTMENT MANAGEMENT S 100191.00 896.00
DIVISLAB 2009-03-26 SR PHOENICIA MAURITIUS LTD P 100191.00 896.00
Dividend history
Ex Date Amount
2020-02-25 16.00
2019-08-14 16.00
2018-08-31 10.00
2017-09-15 10.00
2016-03-17 10.00
2015-08-06 20.00
2014-07-31 20.00
2013-07-25 15.00
2012-07-26 13.00
2011-06-16 10.00
2010-07-02 6.00
2009-06-15 6.00
2008-06-26 4.00
Bonus Data
Company Name Split Date From Value To Value
DIVI'S LABORATORIES LTD. 2015-09-23 1.00 1.00
DIVI'S LABORATORIES LTD. 2009-07-30 1.00 1.00
Split Data
Company Name Split Date From Value To Value